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T cells are critical helper, effector and regulatory immune cells that are essential for life. Reduced T cell numbers and functional deficiencies are causally implicated in diseases ranging from congenital immunodeficiency to autoimmune and impaired immune surveillance disorders 1, 2 . In allogeneic (allo)-HSCT, there is a marked deficiency in T cell generation, which renders patients susceptible to infectious agents and may contribute to graft-versushost disease (GVHD) 3 . These complications can be fatal and limit the use of HSCT in settings where it can be curative. Balanced reconstitution of the naive helper and effector T cell subsets, along with restoration of the T cell receptor (TCR) repertoire, remains a significant unmet clinical need 4 .
T cell regeneration from transplanted hematopoietic cells requires availability of an adequate pool of T cell progenitors 5 arising from bone marrow and sufficient thymic function 6 . Although there is currently no clinical standard for enhancing T cell generation in vivo, most efforts have focused on using cytokines and cell-based therapies from the post-bone marrow phases of T cell lymphopoiesis. However, in clinical trials, the T cell expansion cytokines IL-7 and IL-2 7 increased primarily mature T cell subsets 8 and use of IL-2 was further limited by toxicity 9 . In contrast, administration of IL-22 has been shown to enhance recovery of early thymocytes in preclinical mouse studies 10 . Alternatively, adoptive donor T cell infusion has been used to provide antigen-specific T cell protection against commonly encountered pathogens 11, 12 , but has been associated with a transient response, increased risk of GVHD and T cell exhaustion. The above strategies are all limited by the availability of an adequate pool of T cell progenitors to promote thymus-dependent T cell generation. T cell precursors can be robustly generated ex vivo by activation of Notch signaling, and co-administration of these cells with HSCT improves thymopoiesis and thymic architecture without exogenously co-administered cytokines [13] [14] [15] . However, ex vivo cell culture to generate sufficient numbers of progenitors is laborious and only a transient enhancement in thymopoiesis of donor cells has been demonstrated. Thus, the widespread clinical translation of this approach would likely be complex.
Seeking to develop a broadly applicable technology, we focused on the prethymic bone marrow-resident common lymphoid progenitors (CLPs), which have the capacity to differentiate into naive T lymphocytes when Notch signaling is activated and are a major source of thymopoiesis [16] [17] [18] . The stromal component of the bone marrow niche that enhances T cell lineage specification consists of osteocalcin-expressing bone marrow stromal cells producing delta-like ligand-4 (DLL-4), which provide a functional microenvironment critical for generating T cell-competent CLPs 19 . These stromal cells are damaged by the process of preconditioning, which likely impacts their T cell lineage-instructive function. Additionally, clinical experience in patients with AIDS indicates that the adult thymus has the capacity to markedly improve in cellular composition and T cell neogenesis despite prior dysfunction and atrophy 20 . These prior findings supported the development of a niche based on specific biological aspects of T cell lymphopoiesis in the bone marrow. We hypothesized that a T cell-lymphopoietic bone marrow niche might be engineered to foster production of T cell progenitors in vivo that migrate to the native thymus and thereby undergo hostdriven selection to create a more balanced and broad immune repertoire. We created an injectable, biomaterial-based BMC scaffold that promotes T cell development in vivo by integrating molecular signals that are presented in the bone marrow niche. The BMC comprises a macroporous hydrogel-based scaffold permitting c, Representative SEM image of pore shape and structure within a cross-section of a BMC. Scale bar, 200 μm. d, Release kinetics of the encapsulated BMP-2 (red line) and covalently tethered DLL-4 (green line) (n = 5 per group). e, Surface plasmon resonance measurements of the binding kinetics of DLL-4 before and after modification with the MA linker. f, In vitro differentiation of isolated mouse and human hematopoietic stem and progenitor cells into CLPs as a function of the degree of functionalization of the MA groups on the polymer backbone (n = 5). g, Proportion of lineage-negative (Lin -) common lymphoid and myeloid mouse progenitor cells quantified in growth medium and with blank, single-factor and dual-factor BMCs. Images and pore size quantification in b and c are representative of ten independent replicates. Data in d, f and g represent the mean ± s.d. of five experimental replicates and are representative of three independent experiments. Distinct samples were assayed individually. cellular infiltration. It releases bone morphogenetic protein-2 (BMP-2) to facilitate recruitment of host stromal cells and their osteolineage differentiation and presents bioactive Notch ligand DLL-4 at predefined densities to infiltrating hematopoietic cells.
These T-lineage cues enhanced thymic seeding of progenitors and enabled reconstitution with donor T cells after syngeneic (syn)-and allo-HSCT in mice. BMC-reconstituted T cells were functional, with a diverse TCR repertoire and reduced induction of GVHD.
Results

Bioactive macroporous BMCs differentiate hematopoietic progenitors into progenitor T cells in vitro.
The scaffold-based alginate-PEG BMC is a macroporous hydrogel with interconnected pores 50-80 μm in diameter ( Fig. 1a-c ). DLL-4 was incorporated into the polymer backbone to promote the T cell lineage program in hematopoietic progenitor cells 17 . To enable de novo bone formation 21 , BMP-2 was added to the reaction mixture prior to cryopolymerization for subsequent release in soluble form in vivo. These cryogels present both immobilized (DLL-4) and soluble (BMP-2) cues, unlike previous cryogels, which were solely designed for controlled release of proteins 22 . In this work, the BMC additionally supports the growth of bone and hematopoietic tissue. In vitro BMP-2 release (encapsulation efficiency of 90%) showed an initial burst corresponding to release of about 5% of the loaded amount, and BMP-2 was then released in a sustained manner ( Fig. 1d ). Less than 1% of the total loaded DLL-4 was detected in the supernatant, and modified DLL-4 had similar binding kinetics to that of the unmodified protein ( Fig. 1e ). In the pooled release samples, over 90% of the bioactivity of the released BMP-2, relative to freshly reconstituted BMP-2, was retained ( Supplementary  Fig. 1a ). The bioactivity of BMP-2 ranged from 95% at day 3 of release to ~85% at day 12, confirming that the released BMP-2 is highly active ( Supplementary Fig. 1b ). The highest in vitro bioactivity of DLL-4 was found at early time points, on days 0 and 10 ( Supplementary Fig. 1c,d ). The bioactivity decreased at subsequent time points but was still above baseline after 3 months. To measure the capacity of the BMC to induce differentiation of mouse and human hematopoietic progenitor cells via Notch signaling, primary lineage-depleted bone marrow cells from mice and cord blood-derived human CD34 + hematopoietic cells were cultured in the BMC (Fig. 1f ). Expansion of CLPs was saturated at 1% functionalization of the methacrylate (MA)-COOH groups on the polymer backbone with MA-DLL-4, corresponding to approximately 6 μg of MA-DLL-4 per gel, and this condition was selected for further evaluation. There were no significant differences in the fold expansion and viability numbers of human or mouse cells overall in any of the experimental conditions analyzed ( Supplementary  Fig. 1e ,f). However, the fraction of lymphoid progenitor cells was enhanced only when DLL-4 was incorporated in the BMC, alone or in combination with BMP-2 ( Fig. 1g ).
BMCs form a bone nodule with features of hematopoietic tissue in vivo.
The BMC was next analyzed for its ability to induce trafficking of host and transplanted cells in a mouse model of HSCT. After lethal total-body irradiation (L-TBI), mice were transplanted intravenously with lineage-depleted hematopoietic cells (5 × 10 4 ; ~93% lineage depleted; Supplementary Fig. 2a ) isolated from the bone marrow of donor mice, and BMCs (without cells) were simultaneously injected into the subcutaneous tissue of the dorsal flank ( Fig. 2a ). To grossly quantify cell infiltration in the BMCs, the size of each subcutaneous nodule was measured over a period of 6 weeks ( Fig. 2b ). In the BMC with BMP-2, the size rapidly increased to approximately three times the initial volume by 10 d following transplantation, with substantial infiltration by donor hematopoietic cells ( Fig. 2c ) and formation of a local bone nodule over a period of approximately 2 weeks ( Fig. 2d,e ).
Notably, bone formation was accompanied by vascularization, DLL-4 remained accessible and bone was restricted to the BMC scaffold, demonstrating the control afforded by the BMC over this process at an ectopic site ( Fig. 2f -j, Supplementary Fig. 2b and Supplementary Note 1).
BMCs recruit and expand host stromal and transplanted hematopoietic cells. We assessed the infiltration and cell composition of the transplanted hematopoietic cells in the BMC at various time points after transplantation. Donor GFP + cells expanded when BMP-2 was included, but not in the presence of DLL-4 alone ( Fig. 3a and Supplementary Fig. 2c ). The stromal cells populating BMCs and native bone marrow were found to be similar; there was no difference in engraftment of hematopoietic cells in the native bone marrow of BMC-treated and nontreated mice, and stromal cell-derived factor (SDF)-1α and IL-7 concentrations were similar between the BMCs and native bone marrow ( Supplementary Fig. 2d -g and Supplementary Note 2). At later time points (>5 d after transplantation), more primitive donor hematopoietic cells (hematopoietic stem cells (HSCs) and lymphoid-primed multipotential progenitors (LMPPs)) were quantified in the BMC. At day 14, between 6 and 7 million total GFP + cells were quantified in the BMCs containing single-factor BMP-2 or dual-factor BMP-2 and DLL-4. Over 80% of cells were CD11b + myeloid cells in both groups. However, the CLP fraction in the transplanted donor cells expanded only within dual-factor BMCs, resulting in a ~100-fold increase relative to BMCs with only BMP-2 at 2 weeks after transplantation ( Fig. 3a ). At 6 weeks after transplantation, CLP numbers were ~10-fold higher in dualfactor BMCs, with approximately 30% and 70%, respectively, in the T cell-competent Ly6D − subset (Fig. 3b ). Progenitor T cells from bone marrow migrate to the thymus to differentiate into naive T cells. To directly assess whether cells from the BMC migrate to the thymus, the dual-factor BMC in concert with stem cell therapy was delivered into an initial set of lethally irradiated mice ( Fig. 3c,d ). The dual-factor BMC was then explanted from these mice at day 10 and surgically transplanted into sublethally irradiated recipients subcutaneously in the dorsal flank. On day 20 after BMC transplantation, the donor GFP + and host cells in the thymus of these mice were quantified. GFP + double-positive, single-positive CD4 + and single-positive CD8 + cells were quantified in the thymus of BMC-transplanted recipient mice, confirming migration of T cell progenitor cells from the BMC to the thymus. In a separate study, dual-factor BMC treatment in combination with lineage-depleted transplanted cells resulted in greater enhancement of the number of early thymic progenitors (ETPs) in the thymus even when compared to a tenfold increase in the dose of administered transplanted cells without a BMC (Fig. 3e ).The dual-factor BMC also significantly 
BMCs enhance T cell regeneration after HSCT and mitigate GVHD.
In the peripheral blood of mice treated with the dually functionalized BMC, acceleration in T cell reconstitution was observed approximately 4 weeks after transplantation, but no significant difference was observed in B cell or myeloid cell reconstitution ( Fig. 4a and Supplementary Fig. 3a,b ). An analysis of T cell subsets in the blood, spleen and bone marrow indicated that the homeostatic CD4 + :CD8 + T cell ratio was restored in mice with dually functionalized BMCs 30 d after transplantation in the spleen and bone marrow and 40 d after transplantation in the peripheral blood ( Fig. 4b-d ). When BMC treatment was used in the context of HSCT after sublethal total-body irradiation (SL-TBI), there was enhanced Supplementary Fig. 3c,d ). At 28 d after transplantation, the donor chimerism and absolute number of double-positive donor thymocytes were 1.5-fold and 2-fold higher, respectively, in BMC-treated mice than in mice that received just the transplant (Fig. 4e ). There was also higher donor chimerism and absolute numbers of donor-derived single-positive CD4 + thymocytes (by 2-fold and 3-fold, respectively) and single-positive CD8 + thymocytes (by 1.7-fold and 15-fold, respectively) in BMC-treated mice than in mice that received just the transplant (Fig. 4f,g) . In the periphery, the level of donor chimerism was higher in CD4 + (by 3.5fold) and CD8 + (by 2.5-fold) T cells. No difference was observed in the chimerism or absolute number of B cells.
We next assessed the rate of human T cell reconstitution using an established xenogeneic NSG-BLT mouse model 23 . In BMC-treated NSG-BLT mice, there was early enhancement in the initial rate of T cell reconstitution and a modest, transient reduction in the rate of B cell reconstitution ( Fig. 5a,b) , with transiently fewer pre-B cell colony-forming units (CFUs) in the bone marrow of BMC-treated NSG-BLT mice ( Supplementary Fig. 4 ). The peripheral CD4 + :CD8 + T cell ratio was stabilized in BMC-treated mice between 50 and 60 d after transplantation, whereas the CD4 + compartment in control NSG-BLT mice was not fully reconstituted ( Fig. 5c ). Notably, the enhanced rate of T cell reconstitution did not accelerate the rate of GVHD-related death. Instead, NSG-BLT mice that received the dually functionalized BMC survived longer than control NSG-BLT mice (Fig. 5d ). In BMC-treated NSG-BLT mice, the proportion of CD4 + FoxP3 + regulatory T (T reg ) cells was twofold higher in the thymus and spleen at 50 d after transplantation in this model ( Fig. 5e and Supplementary Fig. 5a ). A similar enhancement in survival was observed in an allogeneic major histocompatibility complex (MHC)mismatch HSCT mouse model that received the BMC (Fig. 5f) , and the proportion of donor-derived CD4 + FoxP3 + T reg cells was five-and fourfold higher in the thymus and spleen, respectively, of BMC-treated mice 15 d after transplantation in this model (Fig. 5g ). We next compared our BMC treatment to a widely studied infusion approach with T cell progenitors, consisting predominantly of double-negative (DN) 2 and DN3 precursors (>90%) generated ex vivo using OP9-DL1 feeder cells ( Supplementary Fig. 5b ). At 28 d after HSCT, donor chimerism was significantly higher in BMCtreated mice in the double-positive, single-positive CD4 + and single-positive CD8 + thymocyte populations ( Fig. 5h-j) . In the spleen, donor chimerism was higher for both CD4 + and CD8 + T cells and higher absolute numbers of donor CD4 + and CD8 + T cells were found with BMC treatment (Fig. 5k,l) .
BMCs enhance the diversity and function of regenerated T cells.
Diversity in TCRs is produced by stochastic somatic recombination of gene segments in the thymus. In dual-factor BMC-treated mice, thymus cellularity and thymus weight were significantly higher than in transplant-only controls up to ~6 weeks after transplantation ( Supplementary Fig. 6a,b ). To characterize whether the increase in thymic cellularity also enhanced the functionality and diversity of the regenerated T cells in syngeneic transplants, we quantified TCR excision circles (TRECs), which are a signature of TCR rearrangement, and conducted a TCR repertoire analysis. TREC numbers in the thymus of dual-factor BMC-treated mice 1 month after transplantation were similar to those in non-irradiated control mice, and both were greater than in transplant-only mice and BMP-2 BMC-treated mice (Fig. 6a ). In the spleen, an overall lower number of TRECs was noted in the same groups relative to the non-irradiated control group, but mice treated with the dual-factor BMC still had a higher TREC count than the transplant-only and single-factor BMP-2 BMC groups (Fig. 6b ). We next evaluated the diversity of TCR V and J segments in the CDR3 β chain of BMCtreated and transplanted mice 30 d after HSCT using Simpson's index (SI), which takes into account the number of T cell clones present, as well as the relative abundance of each clone. The SI of mice with the dually functionalized BMC was 40% that of non-irradiated control mice, whereas the SIs in mice administered the transplant alone or with the BMP-2 BMC were lower (16% and 8%, respectively) ( Fig. 6c ). In HSCT, lack of naive T cells with a broad TCR repertoire has been associated with increased risk of immunological complications and opportunistic infections 24 . Recovery of a greater number of TRECs in the thymus and periphery of dual-factor BMC-treated mice mirrors the enhancement observed in thymopoiesis. Relatively high frequencies of specific TCR clones were also observed in mice treated with the dual-factor BMC, but greater overall diversity suggests more balanced thymus-derived reconstitution.
To measure the capacity of regenerated T cells to respond in an antigen-specific manner, syngeneic transplants were vaccinated and subsequently challenged with a model protein, ovalbumin (OVA), 30 d after transplantation (Fig. 6d ). Numbers of OVA epitope (SIINFEKL)-tetramer + CD8 + T cells were significantly higher in mice that received the dually functionalized BMC, as compared to transplanted mice that did not receive a BMC or received the BMC with BMP-2 only (Fig. 6e) . Similarly, in dual-factor BMC-treated mice that received the allogeneic transplant, the donor antigen-specific T cell response was approximately threefold higher than that resulting from the pro-T cell therapy approach (Fig. 6f ). We found that production of interferon (IFN)-γ and tumor necrosis factor (TNF)-α upon ex vivo stimulation was comparable for donor CD4 + and CD8 + T cells from the BMC treatment and T cell progenitor treatment groups at day 22, but a significantly greater fraction of T cells from the BMC-treated group produced these factors at day 42 (Fig. 6g,h) . The robust antigen-specific generation of CD8 + T cells after vaccination in BMC-treated mice following HSCT suggests that BMC treatment has the potential to be used in combination with post-HSCT vaccination.
Discussion
Here we demonstrate that a cell-free biomaterial-based BMC mimicked key features of the T cell lymphopoietic bone marrow niche and promoted regeneration of immune-competent T cells after HSCT. Subcutaneously administered BMCs interfaced with host vasculature to form a host-device interface and presented lineage-instructive cues to recruited donor progenitor cells in vivo. It is well established that BMP-2 induces osteolineage differentiation of recruited mesenchymal cells and indirectly promotes rapid neoangiogenesis 25 . In this work, we observed early neoangiogenesis, followed by maturation of the vasculature to densities consistent with those observed in endogenous bone marrow 26 . The finding of various hematopoietic and stromal progenitor populations within the BMC is consistent with previous observations of hematopoiesis occurring within an ectopic bone nodule 27, 28 . Incorporation of bioactive Notch ligand DLL-4 on the polymer scaffold promoted early enhancement in the generation of T cell progenitors in the BMC and led to a significant increase in the number of thymic progenitors relative to controls receiving lineage-depleted bone marrow grafts that are similar to established models of syn-and allo-HSCT 29, 30 . This finding is consistent with the observation of enhanced generation of TRECs, increased complexity of the TCR repertoire and increased vaccination efficacy.
The BMC approach is distinct conceptually and in practice from other strategies to promote post-HSCT T cell regeneration, and its relevance in HSCT is supported by the preclinical studies in this work. It resulted in a higher number of T cell progenitors and functional T cells in the thymus and periphery when used with a tenfold lower dose relative to T cell progenitor infusion. BMC treatment varies from other methods in that it can be administered at the time of HSCT. In contrast, T cell progenitors are produced in vitro from donor hematopoietic cells over 2-4 weeks, have complex cell culture requirements in preclinical models and are patient specific. By providing T cell-promoting cues to the transplanted HSCs in vivo without the need for ex vivo culture, the BMC approach may be an off-the-shelf product that avoids the considerable infrastructure needed for cell manufacturing 31 and may complement the activities of cytokine therapies. When a lower radiation dose was used prior to HSCT, the BMC modestly enhanced T cell reconstitution in the periphery but significantly increased donor-derived T cell generation in the thymus and donor T cell chimerism. This finding suggests that application of BMCs will be relevant in settings of lower-intensity HSCT.
The enhancement in reconstitution of human T cells in xenogeneic NSG-BLT mice was accompanied by a modest and transient reduction in B cell reconstitution, consistent with a corresponding decrease in pre-B cell CFUs. Although this humanized mouse model is widely accepted for human immune cells, it is also known that key mouse cytokines are inefficient at inducing hematopoiesis, including the development of human B cells from human CD34 + cells in this model 32 . It is likely that Notch activation of the fraction of transplanted cells, which seed the BMC, enhances T cell specification at the expense of B cell specification. However, the transient reduction in B cell production is modest and unlikely to be of clinical significance.
Formation of a bone nodule is restricted to the geometry of the scaffold, consistent with previous reports of scaffold-induced bone formation, which has been well tolerated in many species, including nonhuman primates 33 and humans 34, 35 . Our clinical experience with other scaffold-based systems indicates that the size of the device may remain constant between species 36 . Even with the larger growth factor dose that might be necessary for use in humans, we anticipate that the controlled release provided by this polymer-based hydrogel system would permit the use of BMP-2 at a dose several orders of magnitude lower than the large doses currently used in the clinic, which are delivered as a bolus release and have been associated with undesirable side effects 37 . After T cell regeneration, the BMC may be readily removed similarly to other devices that are often used in HSCT or may be made with biodegradable materials to resorb 38 .
CD4 + T cell recovery after allo-HSCT is usually delayed, leading to an inversion of the normal CD4 + :CD8 + ratio 39 . In BMCtreated mice, there was more balanced reconstitution of T cells and enhancement in donor CD4 + T reg cells in the thymus and spleen of humanized and allogeneically transplanted mice. Given the key role of donor T reg cells in GVHD suppression 40 , BMC-mediated enhancement of donor T reg cell generation likely contributed to the mitigation of GVHD-like pathology and the enhanced survival of mice, potentially through BMP-2 regulation of TGF-β family proteins, which are key regulators of T reg cell expansion 41 . Moreover, the time course in the allogeneic GVHD model is consistent with at least some of the BMC role being due to an effect on pre-existing T-lineage-committed or mature T cells.
Collectively, these findings suggest that the BMC represents a simple-to-administer system that can enhance T cell regeneration after HSCT. If the BMC system performs similarly in a human context, it may be a means of abrogating the immunological complications and opportunistic infections that limit clinical application of potentially curative HSCT.
Methods
General methods and statistics. Sample sizes for animal studies were based on prior work without use of additional statistical estimations 23, 42, 43 . Results were analyzed by one-way ANOVA with a Tukey post hoc test using GraphPad Prism software. Where ANOVA was used, variance between groups was found to be similar by Bartlett's test. Survival curves were analyzed using the log-rank (Mantel-Cox) test. Alphanumeric coding was used in blinding for pathology samples and blood counting.
Materials. UP LVG sodium alginate with high guluronate content was purchased from ProNova Biomedical; 2-morpholinoethanesulfonic acid (MES), sodium chloride (NaCl), sodium hydroxide (NaOH), N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), 2-aminoethyl methacrylate hydrochloride (AEMA) and acetone were purchased from Sigma-Aldrich. ACRL-PEG-NH 2 (3.5 kDa) and 4-arm PEG acrylate (10 kDa) were purchased from JenKem Technology. BMC fabrication. BMCs were made following a previously described technique with some modifications 44 . Methacrylated alginate (MA-alginate) was prepared by reacting alginate with AEMA. Sodium alginate was dissolved in a buffer solution (0.6% wt/vol, pH ∼6.5) of 100 mM MES buffer. NHS and EDC were added to the mixture to activate the carboxylic acid groups on the alginate backbone followed by AEMA (molar ratio of NHS:EDC:AEMA = 1:1.3:1.1), and the solution was stirred at room temperature for 24 h. The mixture was precipitated in acetone, filtered and dried in a vacuum oven overnight at room temperature. Alginate-PEG BMCs were synthesized by preparing a 2.5% (wt/vol) solution of MA-alginate and 4-arm PEG acrylate macromonomers (molar ratio MA-alginate:4-arm PEG acrylate = 4:1) in deionized water and subsequently adding tetramethylethylenediamine (TEMED; 0.5% wt/vol) and ammonium persulfate (APS; 0.25% wt/vol). ACRYL-PEG-NH 2 was conjugated with DLL-4 (R&D Systems) using carbodiimide chemistry (molar ratio of NHS:EDC:DLL-4 = 1:1.3:1.1). BMP-2 (R&D Systems) was added to the polymer solution before cryopolymerization. All precursor solution was precooled to 4 °C to decrease the rate of polymerization before freezing. After addition of the initiator to the prepolymer solution, the solution was quickly transferred onto a precooled (−20 °C) Teflon mold. After overnight incubation, the gels were thawed and collected in Petri dishes on ice. For scanning electron microscopy, BMCs were incubated in increasing concentrations of freshly prepared ethanol solution (30, 50, 70, 90 and 100%) for 20 min each. BMCs were then incubated in hexamethyldisilazane (Electron Microscopy Sciences) for 10 min and dried in a desiccator/vacuum chamber for at least 1 h prior to mounting them for scanning electron microscopy. Dried BMCs were adhered onto sample stubs using carbon tape and coated with platinum/palladium in a sputter coater. Samples were imaged using secondary electron detection on a Carl Zeiss Supra 55 VP field emission scanning electron microscope.
Biomolecule release quantification. The stock concentration of BMP-2 was known from the manufacturer and verified using ELISA. To determine the release kinetics encapsulation efficiency of BMP-2 and to confirm stable conjugation of DLL-4, BMCs were incubated in 1 ml of sterile PBS at 37 °C with shaking. The medium was replaced periodically. Released agents in the supernatant were detected by ELISA (Peprotech). Samples were released until no more BMP-2 was detectable in the release medium. Subsequently, the cryogel was digested using at least 1,000 U of the enzyme alginate lyase. The digested product was analyzed for BMP-2 by ELISA. The amounts of BMP-2 and DLL-4 in the cryogel and release medium were compared with the known amounts of loaded BMP-2 and DLL-4 to calculate the encapsulation efficiency.
Biomolecule activity assays. Alkaline phosphatase activity assay for BMP-2 bioactivity. MC3T3-E1 Subclone 4 cells were used to conduct an alkaline phosphatase assay as previously described 45 . Cells were cultured under different experimental conditions: (i) growth medium, (ii) differentiation medium supplemented with BMP-2 released from BMCs and (iii) native BMP-2.
Notch activation assay for DLL-4 bioactivity. To quantify the in vitro bioactivity of DLL-4 after exposure to serum proteins, which could deactivate this morphogen in vivo, a previously characterized Notch reporter cell line, CHO-K1+2xHS4-UAS-H2B-Citrine-2xHS4 cH1+hNECD-Gal4esn c9, a kind gift from M. Elowitz (Caltech), was used 46, 47 . These cells were grown in Alpha MEM Earle's Salts (Irvine Scientific) supplemented with 10% Tet System Approved FBS (Clontech), 100 U/ ml penicillin, 100 μg/ml streptomycin and 0.292 mg/ml l-glutamine (Gibco), at 37 °C in the presence of 5% CO 2 under a humidified atmosphere. BMCs both with and without DLL-4 were incubated in 96-well plates with complete cell culture medium, without cells. At predetermined time intervals (up to 3 months), 20,000 Notch reporter cells were seeded in the wells on the BMCs. After 24 h, confocal microscopy was performed using a Zeiss LSM 710 confocal system. The colorimetric output in response to binding with Notch ligand DLL-4 was quantified and used as an indicator of DLL-4 bioactivity in the scaffold ( Supplementary Fig. 1c ). In particular, the total YFP fluorescence of each cell in a field of view (50-100; 4-5 fields of view encompassing over 80% of the gel surface) was calculated and background fluorescence was subtracted. The median YFP fluorescence reported was calculated and divided by the median fluorescence of the cells seeded on the BMCs without DLL-4.
Affinity determination by surface plasmon resonance. Dissociation constants of wild-type DLL-4 and MA-DLL-4 for Notch1 were determined by surface plasmon resonance using a BIAcore T200 instrument (GE Healthcare) as described previously 34 . Briefly, biotinylated recombinant Notch1 was immobilized on a streptavidin-coated sensor chip (GE Healthcare). Increasing concentrations of wild-type methacrylated DLL-4 proteins in buffer were flowed over the chip at 20 °C. Binding and dissociation phases were performed at 10 µl/min for 120 s and 60 s, respectively. Steady-state binding curves were fitted using the BIAcore evaluation software to a 1:1 Langmuir model to determine the dissociation constant.
In vitro cell culture in the BMC. Mouse bone marrow cells were harvested from the limbs. Crushed tissue and cells were filtered through a 70-micron mesh. A single-cell suspension was prepared by passing the cells once through a 20-gauge needle. Total cellularity was determined by counting cells using a hemacytometer. Bone marrow cells were depleted of mature immune cells (expressing CD3ε, CD45R/B220, Ter-119, CD11b or Gr-1) by magnetic selection (BD Biosciences). We incubated cells with a mix of Pacific Blue-conjugated lineage-specific antibodies (antibodies to CD3, NK1.1, Gr-1, CD11b, CD19, CD4 and CD8) and with Sca-1-and c-Kit-specific antibodies. We isolated hematopoietic cells (Lin − Sca-1 hi c-Kit hi ) using a FACSAria cell sorter (BD). Sorted cells were ≥95% pure. Human cord blood-derived CD34 + cells were purchased (Allcells) and expanded for 7 d using expansion supplements (Stemcell Technologies). CD34 + cells were isolated using a positive selection kit (Stemcell Technologies). 96-well plates were precoated with Pluronic F127 (Sigma). Each BMC was individually placed in a well of the 96-well plate. Ten thousand mouse or human cells, isolated as described above, were added to the same well in a 200-μl volume of RPMI 1640 (with l-glutamine) supplemented with 10% FBS and 1% antibiotic and antimycotic solution (containing penicillin, streptomycin and amphotericin B). For mouse cells, the medium was supplemented with 10 ng/ml stem cell factor (SCF; R&D Systems), 10 ng/ml FMS-like tyrosine kinase 3 ligand (Flt3L; R&D Systems) and 1 ng/ml IL-7 (R&D Systems) with a 50% medium exchange step at days 2, 4 and 6. For human cells, the medium was supplemented with 100 ng/ml SCF, 100 ng/ml Flt3L, 100 ng/ml TPO (R&D Systems) and 100 ng/ml IL-7 (R&D Systems). After 1 week of culture, cells were isolated by digesting the BMC with 1 mg/ml alginate lyase (Sigma). The solution was passed through a 70-micron filter and cells were processed for FACS analysis as described below.
Bone marrow transplantation and blood analysis. All animal work was approved by the Harvard Institutional Animal Care and Use Committee (IACUC) and followed the National Institutes of Health guidelines and relevant ethical regulations. C57BL/6 (B6, H-2 b ), BALB/c (H-2 d ), C57BL/6 (CD45.1 + ), CByJ.B6-Tg(UBC-GFP)30Scha/J (GFP) and NSG mice (Jackson Laboratories) were female and between 6 and 8 weeks old at the start of the experiments. All mice in each experiment were age matched and no randomization was performed. The preestablished criteria for animal omission were failure to inject the desired cell dose in transplanted mice and death due to postsurgical complications in humanized mice. Health concerns unrelated to the procedure (for example, malocclusion, severe dermatitis) were criteria for omission and euthanasia.
Transplant models. All total-body irradiation experiments were performed with a cesium-137 gamma-radiation source: SL-TBI (B6 recipients), 1 dose of 500 cGy + 5 × 10 5 lineage-depleted bone marrow cells; syn-HSCT (B6 recipients), 1 dose of 1,000 cGy + 5 × 10 4 to 5 × 10 5 (as indicated in the figures) lineage-depleted GFP + bone marrow cells; allo-HSCT with GVHD (BALB/c MHC-mismatched recipients), 1 dose of 850 cGy + 5 × 10 5 lineage-depleted GFP + bone marrow cells + 1 × 10 6 GFP + splenocytes; allo-HSCT without GVHD (BALB/c MHCmismatched recipients), 1 dose of 850 cGy + 5 × 10 5 lineage-depleted GFP + bone marrow cells or 5 × 10 6 in vitro-generated GFP + T cell progenitors + 10 3 syngeneic HSCs as described elsewhere without modification 48 . Humanized BLT mouse studies were conducted by the MGH and Ragon Institute Human Immune System Mouse Program, with institutional IACUC approval as described previously 23 . Bone marrow cells for transplantation or analysis were harvested by crushing all limbs or one femur, respectively, and processed as described above. While the mice were anesthetized, they received subcutaneous injections of two BMCs, which were suspended in 0.2 ml of sterile PBS, into the dorsal flank by means of a 16-gauge needle. One BMC was injected on each side of the spine and positioned approximately midway between the hind-and forelimbs. Subcutaneous nodule size was quantified over time by measuring the nodule length, width and height using a caliper. All cohorts of mice (typically ten mice per group) were serially bled. White blood cell, hemoglobin, red blood cell, platelet and hematocrit levels were quantified by CBC analysis (Abaxis VetScan HM5).
To directly assess whether cells from the BMC migrate to the thymus, the dual-factor BMC in concert with stem cell therapy was delivered into an initial set of lethally irradiated mice (B6 recipients receiving 1,000 cGy of L-TBI and 5 × 10 5 lineage-depleted GFP + bone marrow cells with the dual-factor BMC. Ten days after HSCT, the dual-factor BMC was explanted and immediately surgically transplanted into the subcutaneous pocket of a second set of B6 mice that had received 500 cGy of SL-TBI 48 h before without any additional cell transplantation. Twenty days after surgery, mice were killed and thymocytes were analyzed in these mice.
Flow cytometry analysis. Anti-mouse antibodies to CD8α (53-6.7), CD3ε (145-2C11), B220 (RA3-6B2), CD11b (M1/70), CD25 (PC61), CD117 (2B8), Sca-1 (D7) and CD127 (A7R34), anti-human antibodies to CD45 (H130), CD3 (HIT3a), CD4 (SK3), CD19 (HIB19), CD34 (581), CD38 (HB-7), CD7 (CD7-6B7), IFN-γ (XMG1.1) and TNF-α (MP6-XT22), and the corresponding isotype control antibodies were purchased from BioLegend. Anti-human antibody to CD8 (RPA-T8) was purchased from BD Biosciences. Anti-CD44 (IM7) antibody was purchased from eBioscience. SIINFEKL tetramer (Alexa Fluor 647 H-2K b OVA) was obtained from the NIH Tetramer Core Facility. All cells were gated based on forward and side scatter characteristics to limit debris, including dead cells. Antibodies were diluted according to the manufacturer's suggestions. Cells were gated based on fluorescence-minus-one controls, and the frequencies of cells staining positive for each marker were recorded. To quantify T, B and myeloid cells, blood samples underwent lysis of red blood cells and were stained with anti-CD45, anti-B220, anti-CD3, anti-CD4, anti-CD8 and anti-CD11b antibodies; absolute numbers of T, B and myeloid cells were calculated using flow cytometry frequencies and white blood cell values obtained by CBC analysis. Analysis was based on donor events within the CD45 + gate for blood cells and the CD45 − gate for stromal cells.
Bone and fat quantification and histology. After euthanasia, BMCs and tissues were explanted. For quantification of bone using bone alkaline phosphatase (BALP), BMCs and femurs were crushed and homogenized and were passed through a 70-micron filter. Subsequently, a BALP ELISA kit (Creative Diagnostics) was used to quantify BALP by following the manufacturer's protocol. An Oil Red O staining kit (Biovision) was used for lipid quantification. Harvested BMCs and bones were washed, fixed, processed and stained following the manufacturer's protocol. BMCs and bone were subsequently crushed, strained and resuspended in equal volumes before measuring absorbance (OD 492 ). For histological staining, tissues were fixed in 4% paraformaldehyde (PFA). PFA-fixed samples were partially decalcified for about 4 h using a rapid decalcifying formic acid-hydrochloric acid mixture (Decalcifying Solution, VWR) and embedded in paraffin wax. Sections (5 µm) of the samples were stained with routine trichrome, Safranin O or Verhoeff-Van Gieson stain.
Quantification of thymic TCR excision circles. TREC quantification was performed as previously described 35 . Briefly, thymi were harvested from nonirradiated C57BL/6 mice, transplanted mice and transplanted mice with an injected BMC (30 d after conditioning). Total DNA was extracted using TRIzol following tissue homogenization in a Bullet Blender Storm BBX24 instrument (Next Advance). DNA was quantified by UV-Vis, and 1 μg of DNA per sample was used as input for real-time PCR. A standard curve of mouse sjTREC plasmid was used to calculate the absolute number of single-joint TRECs (sjTRECs) per sample. TCR analysis. Extracted lymphocyte RNA was quantified using UV-Vis. Equimolar amounts of RNA from each sample were submitted to iRepertoire for sequencing and bioinformatics analysis, where samples were reverse transcribed and amplified using a primer set that specifically amplifies TCRβ RNA. The sequencing results gave a range of total reads and numbers of unique CDR3s for each sample.
Vaccination and non-specific T cell stimulation study. Thirty days after transplantation, animals were immunized with a bolus vaccine containing 100 μg of OVA, 100 μg of CpG-ODN and 1 μg of GM-CSF. After 10 d, animals were challenged with an intravenous injection of OVA. On day 12, spleens were collected from euthanized mice in the vaccination studies. Splenocytes were isolated by mechanical disruption of the spleen against 70-micron cell strainers. Red blood cells in the harvested tissues were lysed and leukocytes were prepared for analysis. For non-specific stimulation, cells were incubated for 5 h with PMA (10 ng/ml) + ionomycin (2 µM). Brefeldin A (10 µg/ml) was added after 2 h of incubation. Cells were then harvested, washed and stained with fluorochromeconjugated antibodies to T cell surface antigens. Subsequently, cells were fixed and permeabilized with fixation/permeabilization solution kit reagents (BD) and stained with IFN-γ-and TNF-α-specific antibodies. 
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Experimental design 1. Sample size
Describe how sample size was determined.
Sample sizes for animal studies were based on prior work (ref. 23, 42, 43) without the use of additional statistical estimations. Results were analyzed by using one-way ANOVA with a Tukey post hoc test using GraphPad Prism software. Where ANOVA was used, variance between groups was found to be similar by Bartlett's test. Survival curves were analyzed by using the log-rank (Mantel-Cox) test.
Data exclusions
Describe any data exclusions.
For in vivo studies, the pre-established criterion for animal omission were failure to inject desired cell dose in transplanted mice and death due to post-surgical complications in humanized mice. Health concerns unrelated to the procedure (e.g., malocclusion, severe dermatitis) were criteria for omission and euthanasia.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All in vitro experiments were conducted at least three times and in vivo studies with the GFP+ donors were conducted at least two times and could be successfully reproduced. Additionally, in the humanized mouse NSG-BLT study, cells from one donor were used to generate mice and conduct one appropriately powered experiment. Three donor tissues were used to conduct three separate experiments and the data from one donor experiment has been presented.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For in vivo transplantation studies, all animals were identically irradiated. The cages that received the BMCs were randomly assigned post-irradiation by researchers who did not conduct the radiation.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For in vivo studies, alphanumeric coding was used to blind pathology samples and blood counting.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons Test values indicating whether an effect is present Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
BD FACS Diva was used to acquire flow cytometry data. Flowjo (ver 7.6) was used to analyze flow cytometry data. Statistical testing was performed using GraphPad Prism v6. Steady-state binding curves for surface plasmon resonance were fitted using the BIAcore evaluation software to a 1:1 Langmuir model to determine the Kd. Zeiss ZEN 2011 software to acquire and process images from confocal microscopy.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
No unique materials were used in this study
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Anti-mouse antibodies to CD8-α (53-6.7), CD3-ε (145-2C11), B220 (RA3-6B2), CD11b (M1/70), CD25 (PC61), CD117 (2B8), Sca-1 (D7), CD127 (A7R34), and anti-human antibodies to CD45 (H130), CD3 (HIT3a), CD4 (SK3), CD19 (HIB19), CD34 (581), CD38 (HB-7) and CD7 (CD7-6B7), IFN-γ (XMG1.1), TNF-α (MP6-XT22) were purchased from BioLegend. Anti-human CD8 (RPA-T8) was purchased from BD Biosciences. CD44 (IM7) was purchased from eBioscience. SIINFEKL tetramer (Alexa Fluor 647 H-2Kb OVA) were obtained from the NIH Tetramer Core Facility.
Eukaryotic cell lines
a. State the source of each eukaryotic cell line used.
MC3T3-E1 Subclone 4 cell line (ATCC) and human cord-blood derived CD34+ cells (AllCells).
CHO-K1 +2xHS4-UAS-H2B-Citrine-2xHS4 cH1 +hNECD-Gal4esn c9, a kind gift from M. Elowitz, were used to quantify Notch bioactivity b. Describe the method of cell line authentication used. The cell lines were previously characterized as referenced in the manuscript and used without further authentication c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines tested negative for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No such cell lines were used.
